SCHEMBL6036262

SCHEMBL6036262

CCCc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1nn(C2CCCCC2)cc1CC(=O)O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 3/20 0.37
PPARA Q07869 3/20 0.37
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
DGAT1 O75907 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
HPGD P15428 1/20 0.34
KDM4E B2RXH2 3/20 0.33
GCGR P47871 1/20 0.33
GCG P01275 3/20 0.33
LMNA P02545 2/20 0.33
S100A4 P26447 1/20 0.32
ABL1 P00519 1/20 0.32
PTGES O14684 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LIPE Q05469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034569 0.89 PPARD (0.35) PPARDPPARAHCRTR1HCRTR2DGAT1
SCHEMBL6035764 0.86 HCRTR1 (0.36) PPARDPPARAHCRTR1HCRTR2SMN1; SMN2
SCHEMBL6036296 0.86 HCRTR1 (0.36) PPARDPPARAHCRTR1HCRTR2SMN1; SMN2
SCHEMBL6034593 0.85 HCRTR1 (0.37) PPARDPPARAHCRTR1HCRTR2DGAT1
SCHEMBL6035046 0.84 HCRTR1 (0.36) PPARDPPARAHCRTR1HCRTR2SMN1; SMN2
SCHEMBL1633759 0.83 HCRTR1 (0.36) PPARDPPARAHCRTR1HCRTR2DGAT1
SCHEMBL6036155 0.83 HCRTR1 (0.36) HCRTR1HCRTR2SMN1; SMN2HPGDKDM4E
SCHEMBL6035725 0.82 HCRTR1 (0.35) PPARDPPARAHCRTR1HCRTR2SMN1; SMN2
SCHEMBL6035863 0.81 PPARD (0.41) PPARDPPARASMN1; SMN2KDM4ELMNA
SCHEMBL6035923 0.80 SMN1; SMN2 (0.36) PPARDPPARAHCRTR1HCRTR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PPARD 2488/4885PPARA 1717/4885HCRTR1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.